Jason Meyenburg
Chief executive: Disc Medicine, Inc. (before 2014 to 28 Feb 2022)
3commitments announced
3with a clear outcome
0met on time
–rate shown after 15 outcomes
Commitments are credited to the chief executive in office on the day they were announced. Where a deadline fell after the leader left, the entry is marked. Sources for each leadership change: Disc Medicine, Inc. filing.
Commitments announced under Jason Meyenburg
| Disc Medicine, Inc.announced 15 Nov 2021 | Provide six-month update from the GEM103 ReGAtta study | Not met31 Dec 2021 |
| Disc Medicine, Inc.announced 15 Nov 2021 | Initiate late-stage trial for GEM103 in patients with GA due after leader left | Withdrawn31 Mar 2022 |
| Disc Medicine, Inc.announced 6 Oct 2021 | Initiate a controlled study of GEM103 in geographic atrophy due after leader left | Withdrawn31 Mar 2022 |
Is this record wrong, or are you Jason Meyenburg? Add a statement or ask for a correction.